胃癌胃切除术中D2淋巴结清扫对比D2淋巴结清扫加完整胃系膜切除的随机临床试验(DCGC01研究)
该随机临床试验将晚期胃癌患者按1:1分配至腹腔镜D2淋巴结清扫组或D2淋巴结清扫加完整胃系膜切除组,主要终点为3年无病生存率。结果显示加用完整胃系膜切除组复发率更低(19.5% vs 29.6%,P=0.032),3年无病生存率更高(85.0% vs 75.5%,log rank P=0.042),但3年总生存率无统计学显著差异(85.8% vs 77.5%,log rank P=0.058)。
要点
- D2+完整胃系膜切除组3年无病生存率为85.0%,D2组为75.5%(log rank P=0.042)。
- D2+完整胃系膜切除组复发33例(19.5%),D2组复发50例(29.6%)(P=0.032)。
- 两组3年总生存率无统计学显著差异(85.8% vs 77.5%,log rank P=0.058)。
核心结论
- 与常规D2清扫相比,D2淋巴结清扫加完整胃系膜切除与更好的无病生存相关,但总生存无统计学显著差异。
研究设计与样本
- 2014年9月至2018年6月期间,晚期胃癌患者按1:1随机分配至腹腔镜D2淋巴结清扫组或D2淋巴结清扫加完整胃系膜切除胃切除术组。
- 改良意向性治疗人群定义为经病理确诊的胃腺癌患者(pT1 N1-3 M0和pT2-4 N0-3 M0)。
- 主要终点为3年无病生存率,次要终点为复发模式和总生存率。
主要发现
- D2淋巴结清扫组169例患者中位随访55个月(四分位距37-60),D2+完整胃系膜切除组169例患者中位随访51个月(四分位距40-60)。
- D2淋巴结清扫组复发50例(29.6%),D2+完整胃系膜切除组复发33例(19.5%)(P=0.032)。
- 3年无病生存率D2组为75.5%(95%CI 68.3%至81.3%),D2+完整胃系膜切除组为85.0%(95%CI 78.7%至89.6%)(log rank P=0.042)。
- Cox回归显示D2+完整胃系膜切除组对比D2组的复发HR为0.64(95%CI 0.41至0.99)(P=0.045)。
- 3年总生存率D2组为77.5%(95%CI 70.4%至83.1%),D2+完整胃系膜切除组为85.8%(95%CI 79.6%至90.2%)(log rank P=0.058);死亡HR为0.64(95%CI 0.41至1.02)(P=0.058)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown whether D2 lymphadenectomy + complete mesogastric excision for gastric cancer improves survival compared with just D2 lymphadenectomy. METHODS: Between September 2014 and June 2018, patients with advanced gastric cancer were randomly assigned (1 : 1) to laparoscopic D2 lymphadenectomy or D2 lymphadenectomy + complete mesogastric excision gastrectomy. The modified intention-to-treat population was defined as patients who had pathologically confirmed gastric adenocarcinoma (pT1 N1-3 M0 and pT2-4 N0-3 M0). The primary endpoint was 3-year disease-free survival. Secondary endpoints were the recurrence pattern and overall survival. RESULTS: The median follow-up of patients in the D2 lymphadenectomy group (169 patients) and patients in the D2 lymphadenectomy +complete mesogastric excision group (169 patients) was 55 (interquartile range 37-60) months and 51 (interquartile range 40-60) months respectively. Recurrence occurred in 50 patients in the D2 lymphadenectomy group (29.6%) versus 33 patients in the D2 lymphadenectomy + complete mesogastric excision group (19.5%) (P = 0.032). The 3-year disease-free survival was 75.5% (95% c.i. 68.3% to 81.3%) in the D2 lymphadenectomy group versus 85.0% (95% c.i. 78.7% to 89.6%) in the D2 lymphadenectomy + complete mesogastric excision group (log rank P = 0.042). The HR for recurrence in the D2 lymphadenectomy + complete mesogastric excision group versus the D2 lymphadenectomy group was 0.64 (95% c.i. 0.41 to 0.99) by Cox regression (P = 0.045). The 3-year overall survival rate was 77.5% (95% c.i. 70.4% to 83.1%) in the D2 lymphadenectomy group versus 85.8% (95% c.i. 79.6% to 90.2%) in the D2 lymphadenectomy + complete mesogastric excision group (log rank P = 0.058). The HR for death in the D2 lymphadenectomy + complete mesogastric excision group versus the D2 lymphadenectomy group was 0.64 (95% c.i. 0.41 to 1.02) (P = 0.058). CONCLUSION: Compared with conventional D2 dissection, D2 lymphadenectomy + complete mesogastric excision is associated with better disease-free survival, but there is no statistically significant difference in overall survival. REGISTRATION NUMBER: NCT01978444 (http://www.clinicaltrials.gov).
引用
- Xie D, Shen J, Liu L, et al. Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study). Br J Surg. 2024. PMID: 38713611. doi:10.1093/bjs/znae106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。